Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

AmoyDx® HRD Focus Panel

Laboratory Developed Test
Related tests:
The AmoyDx® HRD Focus Panel (Reversible Terminator Sequencing) is a next generation sequencing-based in vitro diagnostic test that determines a patient’s HRD status by detecting SNVs and InDels in whole coding regions and intron/exon boundaries of the BRCA1 and BRCA2 genes, and determining a genomic scar score (GSS) using DNA isolated from neutral formalin-fixed paraffin-embedded (FFPE) tissue samples.
Ovarian Cancer
BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset), HRD (Homologous Recombination Deficiency)
Next-Generation Sequencing (NGS)